A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xuping Xie; Antonio E. Muruato; Xianwen Zhang; Kumari G. Lokugamage; Camila R. Fontes-Garfias; Jing Zou; Jianying Liu; Ping Ren; Mini Balakrishnan; Tomas Cihlar; Chien-Te K. Tseng; Shinji Makino; Vineet D. Menachery; John P. Bilello; Pei-Yong Shi

doi:10.1038/s41467-020-19055-7

Nature Communications (Oct 2020)

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xuping Xie,
Antonio E. Muruato,
Xianwen Zhang,
Kumari G. Lokugamage,
Camila R. Fontes-Garfias,
Jing Zou,
Jianying Liu,
Ping Ren,
Mini Balakrishnan,
Tomas Cihlar,
Chien-Te K. Tseng,
Shinji Makino,
Vineet D. Menachery,
John P. Bilello,
Pei-Yong Shi

Affiliations

Xuping Xie: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch
Antonio E. Muruato: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch
Xianwen Zhang: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch
Kumari G. Lokugamage: Department of Microbiology and Immunology, University of Texas Medical Branch
Camila R. Fontes-Garfias: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch
Jing Zou: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch
Jianying Liu: Department of Microbiology and Immunology, University of Texas Medical Branch
Ping Ren: Department of Pathology, University of Texas Medical Branch
Mini Balakrishnan: Gilead Sciences, Inc.
Tomas Cihlar: Gilead Sciences, Inc.
Chien-Te K. Tseng: Department of Microbiology and Immunology, University of Texas Medical Branch
Shinji Makino: Department of Microbiology and Immunology, University of Texas Medical Branch
Vineet D. Menachery: Department of Microbiology and Immunology, University of Texas Medical Branch
John P. Bilello: Gilead Sciences, Inc.
Pei-Yong Shi: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch

DOI: https://doi.org/10.1038/s41467-020-19055-7
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 11

Abstract

Read online

A high-throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening. To address this, Shi and colleagues present a high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV2-Nluc), and show that it has potential for large-scale vaccine evaluation and neutralizing antibody testing.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal